Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
News in Brief

A Tumor Suppressor for Prostate Cancer

DOI: 10.1158/2159-8290.CD-NB10311-23 Published October 2011
  • Article
  • Info & Metrics
  • PDF
Loading

Prostate cancer usually grows so slowly that only about 1% of patients diagnosed with early-stage disease die from it over the next 15 years. But because physicians have no foolproof method to separate aggressive cancers from indolent ones, most patients opt for treatment, risking complications such as impotence and incontinence.

Figure1

Pathologists can diagnose prostate cancer, shown here, with a microscope, but they can't precisely determine how it will behave. [Photo from iStockphoto.]

The discovery of a new prostate cancer tumor suppressor gene, PHLPP1, and studies examining its relationship to the tumor suppressor gene PTEN may simplify decision-making for newly diagnosed patients—and may point to the most effective drugs for recurrent cancers.

Studying mice, researchers at Cold Spring Harbor and other laboratories found that Phlpp1 keeps the oncoprotein Akt in check, much like Pten, which is mutated in roughly half of prostate cancer patients (Cancer Cell 2011;20:173–86). But in Pten-deficient animals lacking both copies of Phlpp1, Akt activity kicked into overdrive. Although the master tumor suppressor p53 delayed progression of the disease, tumors eventually overcame that too.

The researchers then examined more than 200 primary and metastatic tumor samples from men. Almost none of the primary cancers were missing both PTEN and PHLPP1, but both genes were frequently deleted in metastatic tumors, along with p53. By measuring expression levels of PTEN and PHLPP1 in biopsy or prostatectomy samples, doctors could determine the likelihood of an aggressive cancer and the chances of disease recurrence.

“Low RNA transcription activity for these genes seems to herald a future problem,” says Lloyd C. Trotman, PhD, the study's leader. “About 70% of these patients will have a recurrence within 10 years.”

Checking for mutations of PTEN, PHLPP1, and the closely related PHLPP2 in circulating tumor cells in relapsed patients could also help determine which ones would be candidates for clinical trials of drugs that inhibit the PI3-kinase/AKT pathway, when these patients should start taking the drugs (based on p53 status), and which drugs might be optimal for them.

  • ©2011 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 1 (5)
October 2011
Volume 1, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Tumor Suppressor for Prostate Cancer
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
Citation Tools
A Tumor Suppressor for Prostate Cancer
Cancer Discov October 1 2011 (1) (5) 368; DOI: 10.1158/2159-8290.CD-NB10311-23

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Tumor Suppressor for Prostate Cancer
Cancer Discov October 1 2011 (1) (5) 368; DOI: 10.1158/2159-8290.CD-NB10311-23
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Early-Detection Sequencing Assays Prove Highly Specific
  • Vision for NCI Outlined by New Director
  • Combo Therapy for Lung Cancer Extends Survival
Show more News in Brief
  • Home
  • Alerts
  • Feedback
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement